Get the Stockscreener App
16.54
1.10%
0.19
Phreesia Inc stock is traded at $16.54, with a volume of 733.65K.
It is up +1.10% in the last 24 hours and down -19.76% over the past month.
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
See More
Previous Close:
$16.35
Open:
$16.25
24h Volume:
733.65K
Relative Volume:
0.71
Market Cap:
$997.75M
Revenue:
$434.53M
Net Income/Loss:
$-42.72M
P/E Ratio:
-22.35
EPS:
-0.74
Net Cash Flow:
$21.88M
1W Performance:
+4.75%
1M Performance:
-19.76%
6M Performance:
-35.23%
1Y Performance:
-33.51%
1-Day Range:
$16.24
$16.73
1-Week Range:
$15.53
$17.18
52-Week Range:
$15.41
$32.76
Phreesia Inc Stock (PHR) Company Profile
Name
Phreesia Inc
Sector
Industry
Phone
888-654-7473
Address
1521 CONCORD PIKE, WILMINGTON
Compare PHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHR
Phreesia Inc
|
16.55 | 985.69M | 434.53M | -42.72M | 21.88M | -0.74 |
|
VEEV
Veeva Systems Inc
|
217.02 | 36.05B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
66.94 | 12.12B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
43.85 | 8.25B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
95.97 | 8.20B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
35.81 | 6.57B | 11.99B | 24.18M | 234.31M | 0.2956 |
Phreesia Inc Stock (PHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Sep-05-25 | Resumed | DA Davidson | Buy |
| Aug-27-25 | Initiated | Mizuho | Outperform |
| Jan-08-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-26-24 | Initiated | Truist | Buy |
| Jan-17-24 | Upgrade | DA Davidson | Neutral → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Jan-04-23 | Reiterated | Needham | Buy |
| Dec-13-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-13-22 | Initiated | DA Davidson | Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Jan-06-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Sep-02-21 | Reiterated | Needham | Buy |
| Aug-27-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-08-21 | Initiated | Berenberg | Buy |
| Apr-29-21 | Resumed | JP Morgan | Overweight |
| Apr-01-21 | Initiated | Robert W. Baird | Outperform |
| Nov-11-20 | Initiated | Stephens | Overweight |
| Oct-27-20 | Initiated | Needham | Buy |
| Sep-22-20 | Initiated | DA Davidson | Buy |
| Jul-14-20 | Initiated | Citigroup | Neutral |
| May-15-20 | Initiated | Guggenheim | Buy |
| Apr-21-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-13-20 | Initiated | SVB Leerink | Outperform |
| Jan-31-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jan-09-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-19 | Initiated | Raymond James | Outperform |
| Oct-11-19 | Initiated | Robert W. Baird | Outperform |
| Aug-13-19 | Initiated | JP Morgan | Overweight |
| Aug-12-19 | Initiated | Piper Jaffray | Overweight |
| Aug-12-19 | Initiated | Wells Fargo | Outperform |
| Aug-12-19 | Initiated | William Blair | Outperform |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
View All
Phreesia Inc Stock (PHR) Latest News
Phreesia (PHR) Receives Updated Price Target from Barclays | PHR Stock News - GuruFocus
Piper Sandler sees Doximity and Phreesia as oversold, recommends buying By Investing.com - Investing.com Nigeria
Piper Sandler sees Doximity and Phreesia as oversold, recommends buying - Investing.com
Piper Sandler recommends buying Doximity and Phreesia stock after pharma marketing event By Investing.com - Investing.com Canada
Piper Sandler recommends buying Doximity and Phreesia stock after pharma marketing event - Investing.com Canada
Phreesia (PHR) analyst model updated to reflect company’s latest financial guidance for 2026-2027 - MSN
Phreesia (PHR) Analyst Model Updated to Reflect Company’s Latest Financial Guidance for 2026-2027 - Insider Monkey
Phreesia Executive Earns National Spotlight on MM+M’s 2025 40 Under 40 - MyChesCo
Phreesia (PHR) Is Down 19.9% After Profit Turnaround And Higher Revenue OutlookHas The Bull Case Changed? - simplywall.st
Phreesia (PHR) Is Down 19.9% After Profit Turnaround But Soft Revenue OutlookWhat's Changed - Yahoo Finance
Phreesia (PHR) loses 32.2% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Why Phreesia stock plummeted by 23% today - MSN
Phreesia outlines $545M–$559M fiscal 2027 revenue target as AccessOne acquisition expands provider financing and HCP marketing reach - MSN
Phreesia stock price target lowered to $25 at Raymond James on guidance cut - Investing.com Australia
Truist Cuts Price Target on Phreesia to $29 From $36, Keeps Buy Rating - marketscreener.com
Marshall Wace LLP Has $11.91 Million Stock Holdings in Phreesia, Inc. $PHR - MarketBeat
Phreesia stock price target lowered to $25 at Raymond James on guidance cut By Investing.com - Investing.com South Africa
Phreesia adjusts fiscal 2026 revenue outlook; introduces FY27 guidance - MSN
Phreesia (NYSE:PHR) Sees Strong Trading VolumeHere's Why - MarketBeat
Phreesia, Inc. Stock Plummets to New 52-Week Low of $15.41 - Markets Mojo
PHR Analyst Ratings Update: Mizuho Lowers Price Target | PHR Sto - GuruFocus
Mizuho Lowers Phreesia (NYSE:PHR) Price Target to $28.00 - MarketBeat
Phreesia (PHR) Loses 32.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
MercyOne partners with Phreesia to automate social needs screenings - Business Record
Robert W. Baird Cuts Phreesia (NYSE:PHR) Price Target to $25.00 - MarketBeat
PHR Stock: Baird Lowers Price Target, Maintains Outperform Ratin - GuruFocus
Barclays Initiates Coverage on Phreesia (NYSE:PHR) - MarketBeat
Phreesia (NYSE:PHR) Upgraded at Zacks Research - MarketBeat
Phreesia stock hits 52-week low at $18.17 amid market challenges - Investing.com Canada
Citizens reiterates Market Outperform rating on Phreesia stock at $34 By Investing.com - Investing.com Australia
Why Phreesia Stock Plummeted by 23% Today - Yahoo Finance
Mizuho lowers Phreesia stock price target to $28 on pharma spending concerns - Investing.com Nigeria
Mizuho lowers Phreesia stock price target to $28 on pharma spending concerns By Investing.com - Investing.com South Africa
Phreesia, Inc. SEC 10-Q Report - TradingView — Track All Markets
PHR: Citigroup Lowers Price Target While Maintaining Buy Rating - GuruFocus
Citigroup Issues Pessimistic Forecast for Phreesia (NYSE:PHR) Stock Price - MarketBeat
Is Phreesia a Hidden Opportunity After Recent Digital Patient Intake Partnerships? - Yahoo Finance
JPMorgan Chase & Co. Cuts Phreesia (NYSE:PHR) Price Target to $29.00 - MarketBeat
Needham Reiterates Buy Rating for Phreesia (PHR) with $35 Price Target | PHR Stock News - GuruFocus
Canaccord Genuity Lowers Price Target for Phreesia (PHR) | PHR S - GuruFocus
Canaccord Genuity lowers Phreesia stock price target to $33 on revenue outlook - Investing.com Nigeria
Canaccord Genuity lowers Phreesia stock price target to $33 on revenue outlook By Investing.com - Investing.com South Africa
DA Davidson reiterates Buy rating on Phreesia stock, maintains $35 price target - Investing.com Nigeria
Phreesia (PHR) Gains Momentum with New "Overweight" Rating by Ba - GuruFocus
Phreesia (NYSE:PHR) Reaches New 52-Week LowHere's Why - MarketBeat
DA Davidson reiterates Buy rating on Phreesia stock, maintains $35 price target By Investing.com - Investing.com South Africa
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More - ts2.tech
Phreesia stock hits 52-week low at $18.17 amid market challenges By Investing.com - Investing.com South Africa
Phreesia Posts Solid Earnings But Shares Drop Anyway - Yahoo Finance
Phreesia, Inc. (NYSE:PHR) Q3 2026 earnings call transcript - MSN
Phreesia, Inc. (NYSE:PHR) Q3 2026 Earnings Call Transcript - Insider Monkey
Phreesia Inc Stock (PHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):